New Delhi, Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic antidepressant drug.
The company's Singapore-based step-down wholly-owned subsidiary, Strides Pharm Global Pte Ltd, has received approval from the US Food and Drug Administration (USFDA) for Fluoxetine Tabs (10 and 20 mg), the pharmaceutical firm said in a regulatory filing. Said. ,
The company's product is therapeutically equivalent to Eli Lilly's Proza tablets.
According to IMS, the market size of fluoxetine tablets is US$23.9 million.
The Bengaluru-based firm said this approval further strengthens the company's presence in the fluoxetine portfolio, complementing the existing approval of fluoxetine capsules, which has a market size of USD106 million.
Fluoxetine is used to treat major depressive disorder (MDD), obsessive compulsive disorder (OCD).
The company's Singapore-based step-down wholly-owned subsidiary, Strides Pharm Global Pte Ltd, has received approval from the US Food and Drug Administration (USFDA) for Fluoxetine Tabs (10 and 20 mg), the pharmaceutical firm said in a regulatory filing. Said. ,
The company's product is therapeutically equivalent to Eli Lilly's Proza tablets.
According to IMS, the market size of fluoxetine tablets is US$23.9 million.
The Bengaluru-based firm said this approval further strengthens the company's presence in the fluoxetine portfolio, complementing the existing approval of fluoxetine capsules, which has a market size of USD106 million.
Fluoxetine is used to treat major depressive disorder (MDD), obsessive compulsive disorder (OCD).
